140 results match your criteria: "University Claude Bernard Lyon I[Affiliation]"
Neuro Oncol
December 2024
Genetics Department, Institut Curie, Paris, France.
Background: Medulloblastoma (MB) is one of the most prevalent embryonal malignant brain tumors. Current classification organizes these tumors into four molecular subgroups (WNT, SHH, Group 3, and Group 4 MB). Recently, a comprehensive classification has been established, identifying numerous subtypes, some of which exhibit a poor prognosis.
View Article and Find Full Text PDFOncologist
December 2024
Département d'Oncologie Médicale, Institut Paoli-Calmettes, Marseille, France.
Background: In PAOLA-1/ENGOT-ov25, the addition of olaparib to bevacizumab maintenance improved overall survival in patients with newly diagnosed advanced ovarian cancer. We describe the safety profile and quality of life (QoL) of this combination in older patients in PAOLA-1.
Methods: Safety (CTCAE v4.
Cancers (Basel)
October 2024
Department of Neurosurgery, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, 69677 Bron, France.
: The aim was to determine the complication rate and the predictors of complications and survival in high-grade glioma surgically managed at progression with implantation of Carmustine wafers. : A retrospective series of 53 consecutive patients operated on between 2017 and 2022 was built. : The median age was 55 ± 10.
View Article and Find Full Text PDFSci Rep
August 2024
Medical Intensive Care, Pavillon N, Hospices Civils de Lyon, Groupement Hospitalier Edouard Herriot, Lyon-Nord Medical School, University Claude Bernard Lyon I, 5 Place d'Arsonval, 69003, Lyon, France.
Carbon dioxide rebreathing (CO rebreathing) significantly influences respiratory drive and the work of breathing during BiPAP ventilation. We analyzed CO movement during BiPAP ventilation to find a method of real time detection of CO rebreathing without the need of CO concentration measurement sampled from the circuit (method expensive and not routinely used). Observational study during routine care in 15 bed university hospital ICU.
View Article and Find Full Text PDFQ J Exp Psychol (Hove)
June 2024
School of Psychology, University of Kent, Canterbury, UK.
Visual objects in the peripersonal space (PPS) are perceived faster than farther ones appearing in the extrapersonal space (EPS). This shows preferential processing for visual stimuli near our body. Such an advantage should favour visual perceptual learning occurring near, as compared with far from observers, but opposite evidence has been recently provided from online testing protocols, showing larger perceptual learning in the far space.
View Article and Find Full Text PDFCancers (Basel)
March 2024
Department of Medical Oncology, University Claude Bernard Lyon I, 69008 Lyon, France.
Background: Whether re-excision (RE) of a soft tissue sarcoma (STS) of limb or trunk should be systematized as adjuvant care and if it would improve metastatic free survival (MFS) are still debated. The impact of resection margins after unplanned macroscopically complete excision (UE) performed out of a NETSARC reference center or after second resection was further investigated.
Methods: This large nationwide series used data from patients having experienced UE outside of a reference center from 2010 to 2019, collected in a French nationwide exhaustive prospective cohort NETSARC.
JAMA Netw Open
April 2024
Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology, Medical Faculty, University Hospital Cologne, Cologne, Germany.
Importance: Testing for homologous recombination deficiency is required for the optimal treatment of high-grade epithelial ovarian cancer. The search for accurate biomarkers is ongoing.
Objective: To investigate whether progression-free survival (PFS) and overall survival (OS) of patients with high-grade epithelial ovarian cancer treated with maintenance olaparib or placebo differed between patients with a tumor BRCA-like genomic profile and patients without a tumor BRCA-like profile.
Proc Natl Acad Sci U S A
April 2024
Epigenomics and Mechanisms Branch, International Agency for Research on Cancer, World Health Organization, Lyon 69366 Cedex 07, France.
Epstein-Barr Virus (EBV) infects more than 90% of the adult population worldwide. EBV infection is associated with Burkitt lymphoma (BL) though alone is not sufficient to induce carcinogenesis implying the involvement of co-factors. BL is endemic in African regions faced with mycotoxins exposure.
View Article and Find Full Text PDFEur J Cancer
May 2024
Association de Recherche Cancers Gynécologiques (ARCAGY-GINECO), Paris, France.
Nat Cancer
April 2024
Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cell Rep Med
December 2023
SOPHiA GENETICS, La Piéce 12, 1180 Rolle, Switzerland. Electronic address:
Homologous recombination deficiency (HRD) is a predictive biomarker for poly(ADP-ribose) polymerase 1 inhibitor (PARPi) sensitivity. Routine HRD testing relies on identifying BRCA mutations, but additional HRD-positive patients can be identified by measuring genomic instability (GI), a consequence of HRD. However, the cost and complexity of available solutions hamper GI testing.
View Article and Find Full Text PDFOncogene
November 2023
Inserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.) Team, Institut Curie and Paris Sciences Lettres Research University, Paris, France.
The bevacizumab (bev)/olaparib (ola) maintenance regimen was approved for BRCA1/2-mutated (BRCAmut) and Homologous Recombination Deficient (HRD) high-grade Advanced Ovarian Cancer (AOC) first line setting, based on a significantly improved progression-free survival (PFS) compared to bev alone in the PAOLA-1/ENGOT-ov25 trial (NCT02477644), where HRD was detected by MyChoice CDx PLUS test. The academic shallowHRDv2 test was developed based on shallow whole-genome sequencing as an alternative to MyChoice. Analytical and clinical validities of shallowHRDv2 as compared to MyChoice on 449 PAOLA-1 tumor samples are presented.
View Article and Find Full Text PDFPsychon Bull Rev
June 2024
School of Psychology, University of Kent, Canterbury, CT2 7NP, UK.
Visual shape discrimination is faster for objects close to the body, in the peripersonal space (PPS), compared with objects far from the body. Visual processing enhancement in PPS occurs also when perceived depth is based on 2D pictorial cues. This advantage has been observed from relatively low-level (detection, size, orientation) to high-level visual features (face processing).
View Article and Find Full Text PDFBull Cancer
January 2024
Gustave-Roussy, Département de Biopathologie, Unité 981, Villejuif, France.
Histopathology
January 2024
Department of Pathology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, France.
Aims: Struma ovarii (SO) are rare, accounting for 0.3-1% of ovarian tumours, and include benign and malignant lesions. In most cases, histology is not predictive of clinical outcome and prognosis.
View Article and Find Full Text PDFRes Pract Thromb Haemost
August 2023
Swedish Orphan Biovitrum AB, Stockholm, Sweden.
Background: Recurrent joint bleeds are a major cause of morbidity in severe hemophilia. Prophylaxis with efmoroctocog alfa (a recombinant factor VIII Fc fusion protein, [rFVIIIFc]) has demonstrated benefits beyond bleed control, including joint health maintenance.
Objectives: To assess long-term efficacy and safety of rFVIIIFc prophylaxis in severe hemophilia A in phase 3 pivotal (A-LONG/Kids A-LONG) and extension (ASPIRE) studies.
Int J Gynaecol Obstet
March 2024
Lady Davis Institute for Cancer Research, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
Objectives: To evaluate the performance of ChatGPT in a French medical school entrance examination.
Methods: A cross-sectional study using a consecutive sample of text-based multiple-choice practice questions for the Parcours d'Accès Spécifique Santé. ChatGPT answered questions in French.
ESMO Open
October 2023
Oncology Clinical Development, Cell and Gene Therapy, GSK, Waltham, USA.
Synovial sarcoma (SS) is a rare and aggressive disease that accounts for 5%-10% of all soft tissue sarcomas. Although it can occur at any age, it typically affects younger adults and children, with a peak incidence in the fourth decade of life. In >95% of cases, the oncogenic driver is a translocation between chromosomes X and 18 that leads to the formation of the SS18::SSX fusion oncogenes.
View Article and Find Full Text PDFCancers (Basel)
June 2023
Institut für Hämatopathologie Hamburg, 22547 Hamburg, Germany.
The worldwide approval of the combination maintenance therapy of olaparib and bevacizumab in advanced high-grade serous ovarian cancer requires complex molecular diagnostic assays that are sufficiently robust for the routine detection of driver mutations in homologous recombination repair (HRR) genes and genomic instability (GI), employing formalin-fixed (FFPE) paraffin-embedded tumor samples without matched normal tissue. We therefore established a DNA-based hybrid capture NGS assay and an associated bioinformatic pipeline that fulfils our institution's specific needs. The assay´s target regions cover the full exonic territory of relevant cancer-related genes and HRR genes and more than 20,000 evenly distributed single nucleotide polymorphism (SNP) loci to allow for the detection of genome-wide allele specific copy number alterations (CNA).
View Article and Find Full Text PDFJCO Precis Oncol
June 2023
Hôpitaux Universitaires de Genève, Department of Clinical Pathology, Geneva, Switzerland.
Virchows Arch
June 2023
Department of Pathology - Hospices Civils de Lyon - Centre Hospitalier Lyon Sud, University Claude Bernard Lyon I, 69495 Pierre Bénite, Lyon, France.
BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus trametinib (MEK inhibitor) in eight cohorts of patients with BRAFV600E-mutated advanced rare cancers: anaplastic thyroid carcinoma (n = 36), biliary tract cancer (n = 43), gastrointestinal stromal tumor (n = 1), adenocarcinoma of the small intestine (n = 3), low-grade glioma (n = 13), high-grade glioma (n = 45), hairy cell leukemia (n = 55) and multiple myeloma (n = 19). The primary endpoint of investigator-assessed overall response rate in these cohorts was 56%, 53%, 0%, 67%, 54%, 33%, 89% and 50%, respectively.
View Article and Find Full Text PDFCancers (Basel)
March 2023
Centre Léon Bérard, University Claude Bernard Lyon I, 69373 Lyon CEDEX 08, France.
Endometrial cancer (EC) is the seventh most common tumor in women, and prognosis of recurrent and metastatic disease is poor. Cervical cancer (CC) represents the fifth most common gynecological cancer. While ECs are more common in developed countries, the incidence of CC has decreased due to the recent implementation of large screening and vaccination programs.
View Article and Find Full Text PDFJAMA Oncol
May 2023
Surgery Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Importance: Preclinical data about the synergistic activity of radiotherapy (RT) and trabectedin have been reported. The combination of trabectedin and RT in treating myxoid liposarcomas appears worth exploring.
Objective: To explore the effectiveness and safety of trabectedin combined with RT.
J Clin Med
March 2023
Research Center of Brain and Cognition, CerCo, CNRS, 31000 Toulouse, France.
Unilateral hearing loss (UHL) leads to an alteration of binaural cues resulting in a significant increment of spatial errors in the horizontal plane. In this study, nineteen patients with UHL were recruited and randomized in a cross-over design into two groups; a first group ( = 9) that received spatial audiovisual training in the first session and a non-spatial audiovisual training in the second session (2 to 4 weeks after the first session). A second group ( = 10) received the same training in the opposite order (non-spatial and then spatial).
View Article and Find Full Text PDF